Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 213

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study

Pirker, Walter, Djamshidian, Schiva, Asenbaum, Susanne, Gerschlager, Willibald, Tribl, Gotthard, Hoffmann, Martha, Brücke, Thomas·2002·Movement Disorders

Abstract

Atypical parkinsonian syndromes (APS) such as multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration are characterized by poor response to antiparkinsonian medication and rapid clinical deterioration. We used SPECT and [123 I]β‐CIT as a label of dopamine transporters to study the progression of presynaptic dopaminergic degeneration in Parkinson's disease (PD) and APS. Twenty‐four PD patients with short disease duration (2.4 ± 1.5 years), 12 PD patients with long disease duration (9.2 ± 2.6 years), 10 patients with APS (disease duration 2.1 ± 1.5 years), and nine patients with essential tremor (ET) underwent sequential [123 I]β‐CIT SPECT imaging with an interval of 25.5 ± 10.3 (13–63) months. The age‐related decline of striatal β‐CIT binding was studied cross‐sectionally in 30 healthy subjects. The ratio of striatum/cerebellum −1 at 20 hours after tracer injection, reflecting specific‐to‐nondisplaceable binding, was used as the primary SPECT outcome measure. At scan 1, striatal β‐CIT binding was reduced in PD patients with short disease duration (−42% compared with age‐corrected normal values) and long disease duration (−51%), and APS (−36%), but normal in ET. During the observation period striatal β‐CIT binding significantly declined in patients with APS (14.9% per year) and short duration PD (7.1% per year), whereas PD patients with long disease duration and patients with ET showed no significant change of striatal β‐CIT binding between scans 1 and 2. The relative annual reduction from age‐corrected normal values at the time of scan 1 was significantly higher in patients with APS than in PD patients with short disease duration (9.6 vs. 4.3%, P = 0.004). These results demonstrate a rapid decline of striatal β‐CIT binding in patients with atypical parkinsonian syndromes, exceeding the reduction in PD. The dopaminergic degeneration in PD appears to slow down during the course of the disease. SPECT with [123 I]β‐CIT is a sensitive marker of disease progression in parkinsonian disorders. © 2001 Movement Disorder Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.1265

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 213

Metadata

Authors
Pirker, W., Djamshidian, S., Asenbaum, S., Gerschlager, W., Tribl, G., Hoffmann, M., & Brücke, T.
Venue
Movement Disorders
Publisher
Wiley
Published
2002-01
Volume
17
Issue
1
Pages
45-53
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W1980549254
Cited by
213
References
1
FWCI
10.46
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study. https://app.cochat.ai/papers/10.1002/mds.1265
The paper
Pirker, W., Djamshidian, S., Asenbaum, S., Gerschlager, W., Tribl, G., Hoffmann, M., & Brücke, T. (2002). Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study. Movement Disorders. https://doi.org/10.1002/mds.1265

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.